7.7.2.1. first-line chemotherapy patients fit combination therapy. 7.7.2.1.1. enfortumab vedotin plus pembrolizumab combination enfortumab vedotin (ev) plus pembrolizumab represents new standard care patients deemed fit combination therapies. based ev-302/keynote 39a, phase iii trial tested antibody drug conjugate ev directed nectin-4 (ev: administered number times progression) combination immune checkpoint inhibitor, pembrolizumab (maximum 35 cycles) platinum-based chemotherapy (cisplatin carboplatin permitted) combination gemcitabine (up 6 cycles) first-line advanced unresectable metastatic urothelial carcinoma. 30% patients control arm received switch maintenance immunotherapy avelumab. co-primary endpoints, pfs os clearly met significant improvement median pfs 12.5 vs 6.3 months (hr 0.45 (0.38-0.54) median os 31.5 vs. 16.1 months (hr 0.47 (0.38-0.58), respectively. overall orr 67.7% including 29.1% complete remissions (cr) compared 44.4% (12.5% cr) platinum-based chemotherapy (p<0.00001). pre-specified subgroups benefited equally ev+pembrolizumab regardless cisplatin eligibility, pd-l1 expression presence liver metastases. treatment-related toxicity grade≥ 3 reported 55% ev/pembrolizumab versus 70% chemotherapy arm. specific relevant ev toxicities include skin rash, peripheral neuropathy, ocular disorders hyperglycemia. toxicity ev/pembrolizumab needs managed proactively attentively avoid severe sequelae. administration ev/pembrolizumab requires adequate knowledge care specialised interprofessional team . combination ev pembrolizumab first-line treatment 45 cisplatin-ineligible patients locally-advanced/metastatic uc also investigated ev-103, phase 1b/2 study, demonstrated confirmed objective response rate median nine cycles 73.3% complete response rate 15.6% . median duration response median os 25.6 months 26.1 months, respectively. common treatment-related aes peripheral sensory neuropathy (55.6%), fatigue (51.1%), alopecia (48.9%) . second cohort within study randomly assigned previously untreated cisplatin-ineligible patients ev alone ev pembrolizumab . orr 64.5% (95% ci, 52.7 75.1) 45.2% (95% ci, 33.5 57.3) patients treated ev+ pembrolizumab (n = 76) ev monotherapy (n = 73), respectively. median dor reached combination 13.2 months monotherapy. based results enfortumab vedotin plus pembrolizumab granted fda accelerated approval patients locally advanced metastatic uc ineligible cisplatin-containing chemotherapy. 7.7.2.1.2. paitents eligible combination therapy eligible ev ev available spite recent results ev-302/keynote 39a study, ev available different countries. moreover, patients might eligible refuse treatment ev including patients uncontrolled diabetes, peripheral neuropathy grade ≥ 2 pre-existing significant skin disorders. platinum-based chemotherapy integration checkpoint inhibitors represents preferred options patients. general presumptions cisplatin- carboplatin-based therapy remain unchanged case outlined below. 7.7.2.1.2.1.patients fit cisplatin cisplatin-containing combination chemotherapy standard care since late 1980s demonstrating os 12 14 months different series (for review see ). methotrexate, vinblastine, adriamycin plus cisplatin gc achieved survival 14.8 13.8 months, respectively . overall response rates 46% mvac 49% gc. lower toxicity gc compared standard mvac resulted gc becoming standard regimen. dose-dense mvac combined granulocyte colony-stimulating factor (g-csf) less toxic efficacious standard mvac terms of, complete response (cr), 2-year os. however, significant difference median survival two regimens . intensification treatment using paclitaxel, cisplatin gemcitabine (pcg) triplet regimen result significant improvement os intention-to-treat (itt) population phase iii rct, comparing pcg gc . similarly, addition angiogenesis inhibitor bevacizumab gc result os improvement . disease sites impact long-term survival. ln-only disease, 20.9% patients alive five years compared 6.8% patients visceral metastases . trials long-term follow-up, approximately 10-15% patients metastatic uc alive 5 years longer, suggesting sustained benefit cisplatin-based chemotherapy minority patients . carboplatin-containing chemotherapy, without inclusion immunotherapy, considered equivalent cisplatin-based combinations, considered interchangeable standard patients fit cisplatin. comparative analysis four randomised phase ii trials carboplatin vs. cisplatin combination chemotherapy demonstrated lower cr rates shorter os carboplatin arms .a retrospective study highlighted importance applying cisplatin cisplatin-eligible patients order maintain benefit . switch maintenance immunotherapy platinum-based chemotherapy randomised phase ii trial evaluated switch maintenance treatment pembrolizumab patients achieving least stable disease platinum-based first-line chemotherapy. primary endpoint pfs met (5.4 months vs. 3.0 months, hr: 0.65, p = 0.04) . javelin bladder 100 study investigated impact switch maintenance pd-l1 inhibitor avelumab initial treatment platinum-gemcitabine chemotherapy. patients achieving least stable disease better 4–6 cycles platinum-gemcitabine randomised avelumab best supportive care (bsc). overall survival primary endpoint improved 21.4 months avelumab compared 14.3 months bsc (hr: 0.69, 95% ci: 0.56–0.86; p < 0.001). patients discontinued bsc received subsequent treatment 53% received immunotherapy. immune-related aes occurred 29% patients 7% experienced grade 3 complications . patient-reported ouctomes javelin bladder 100 demonstrated detrimental effect quality life . maintenance io avelumab recently standard care patients least stable disease first-line platinum-based chemotherapy. patients fit cisplatin, results checkmate 901 considered . trial tested addition nivolumab combination gemcitabine/cisplatin (gc) followed nivolumab maintenance (until progression maximum 24 months) compared gc alone. note, 9% control arm received switch maintenance therapy avelumab. co-primary endpoints, pfs os reached median pfs 7.9 vs 7.6 months (hr 0.72, 95%ci 0.59-0.88) median os 21.7 vs. 18.9 months (hr 0.78, 95%ci 0.63-0.96). response rate improved gc plus nivolumab (57.6% vs 43.1.%). complete remission (cr) achieved 21.7% patients nivolumab plus gc duration 37.1 months. nivolumab plus gc higher treatment related grade ≥3 toxicity (62% vs 52%). combination represents alternative gc followed maintenance therapy avelumab patients eligible ev ev available. 7.7.2.1.2.2.patients fit carboplatin (but unfit cisplatin) 50% patients fit cisplatin-containing chemotherapy may candidates carboplatin . randomised phase ii/iii trial setting conducted eortc compared two carboplatin-containing regimens (methotrexate/carboplatin/vinblastine [m-cavi] gemcitabine/carboplatin [gemcarbo]) patients unfit cisplatin. eortc definitions eligibility gfr < 60 ml/min and/or ps 2. severe acute toxicity 13.6% gemcarbo vs. 23% m-cavi, orr 42% gemcarbo 30% m-cavi, respectively . based results combination carboplatin gemcitabine considered standard care patient group. importantly, ev-302/keynote 39a javelin bladder 100 included patients fit carboplatin, checkmate 901 included patients fit cisplatin only. combinations gemcitabine paclitaxel studied first-line treatment produced response rates 38% 60% never tested rcts [505-507]. randomised phase ii trial assessed efficacy tolerability profile two vinflunine-based regimens (vinflunine/gemcitabine vs. vinflunine/carboplatin). regimens showed equal orr os less haematologic toxicity combination vinflunine/gemcitabine . non-platinum combination chemotherapy nevertheless recommended first-line use platinum-eligible patients. use single-agent chemotherapy associated varying response rates. responses single agents usually short, complete responses rare, long-term dfs/os reported. recommended first-line treatment metastatic uc.